stopped early after an unplanned safety analysis, found a statistically signifi cant higher median survival in the placebo group than in the treated group . In this study, the risk of venous thromboembolism was 9% in the placebo group and 39% in the group treated with erythropoiesis-stimulating agents. Two subsequent meta-analyses of randomized trials of the use of erythropoiesis-stimulating agents in the management of anemia ( 7 , 8 ) have reported a 50% -60% increase in the risk of venous thromboembolism in patients treated with erythropoiesis-stimulating agents compared with observation or placebo. The increased mortality associated with treatment with erythropoiesis-stimulating agents was uncertain until a 2008 metaanalysis that included data from newer trials ( 9 ) reported a 57% increase in the risk of venous thromboembolism and a small but statistically signifi cant increase in mortality (hazard ratio [HR] = 1.10, 95% confi dence interval [CI] = 1.01 to 1.20) ( 9 ) . However, no increased risk of death has been observed among patients treated with erythropoiesis-stimulating agents who were also receiving chemotherapy (HR = 1.04, 95% CI = 0.97 to 1.11) ( 10 ) .
Although erythropoiesis-stimulating agents appear to increase venous thromboembolism and possibly mortality in randomized trials, little is known about the patterns of erythropoiesis-stimulating agent use and associated outcomes in community practice. We used a retrospective cohort study to evaluate the patterns and predictors of the use of erythropoiesis-stimulating agents in elderly cancer patients with one of four common malignancies who were also receiving chemotherapy. In addition, we evaluated the impact of erythropoiesis-stimulating agents on the blood transfusion rate, long-term risk of venous thromboembolism, and overall survival in the 10 years after these agents were approved by the US FDA.
Patients and Methods

Data Source
We analyzed patient data from the Surveillance, Epidemiology, and End Results (SEER) -Medicare database ( 11 ) . The SEER database contained records of patients diagnosed with cancer in regions that represented approximately 14% of the US population; in 2000, this database was expanded to include approximately 26% of the US population. SEER provides information on tumor histology, location, stage of disease, treatment, and survival, along with demographic and selected census tract -level information. The Medicare database includes Medicare A (inpatient) and B (outpatient) eligibility status, billed claims, and diagnoses. These two files are linked and provide the ability to define a populationbased cancer population, to determine who has been treated with an erythropoiesis-stimulating agent or not, and then to estimate the subsequent risk of outcomes such as need for transfusions and/or venous thromboembolism.
Cohort Selection
We identified all individuals who were aged 65 years or older; who had a pathologically confirmed primary diagnosis of diffuse large B-cell lymphoma ( ( 12 ) from January 1, 1991, through December 31, 2002 ; and who were treated with chemotherapy. These cancers were thought to represent common cancers for which erythropoiesis-stimulating agents were frequently used. We excluded patients who were enrolled in a non-Medicare health maintenance organization because the billing claims for these patients are not submitted to Medicare for reimbursement. Patients who were enrolled in Medicare because of end-stage renal disease and dialysis rather than age were also excluded. Age at diagnosis was categorized into 5-year intervals starting at age 65 years. We recoded the SEER marital status variable as married, not married, and unknown.
Socioeconomic Status Score
We generated an aggregate socioeconomic status score from education, poverty, and income data from the 2000 census tract data, as described previously by Du et al. ( 13 ) . Patients ' scores were ranked on a scale of 1 -5 by use of the formula that incorporated education, poverty, and income weighted equally, with 1 being the lowest value ( 12 ) . In the final analysis, patients with scores of 1 and 2 were combined into one group.
CONTEXT AND CAVEATS
Prior knowledge
Although erythropoiesis-stimulating agents have been approved to reduce the number of blood transfusions required during chemotherapy, increased risks of venous thromboembolism and mortality have been reported.
Study design
Patients who were aged 65 years or older; who were diagnosed with colon, non -small cell lung, or breast cancer or diffuse large B-cell lymphoma in 1991 -2002; and who received chemotherapy were identified in the Surveillance, Epidemiology, and End ResultsMedicare database. The association between erythropoiesisstimulating agent use and venous thromboembolism and overall survival were analyzed.
Contribution
The proportion of patients receiving erythropoiesis-stimulating agents increased approximately 10-fold from 1991 through 2002. The rate of blood transfusion per year during 1991 -2002 remained constant at 22%. More patients who received an erythropoiesisstimulating agent than patients who did not developed venous thromboembolism. Overall survival was similar in both groups.
Implications
Further efforts are warranted to monitor the use and long-term toxicity of expensive oncology drugs, such as erythropoiesisstimulating agents, to ensure that the benefits of any drug outweigh the risks in community practice.
Limitations
It is possible that venous thromboembolism would be diagnosed but not reflected in the billing claims used from the database and that not all treatments with erythropoiesis-stimulating agents or all transfusions were captured. Hemoglobin levels for individual patients were not available. We classifi ed patients into the following three groups: those who received chemotherapy only as nonmetastatic, those who received chemotherapy only with metastatic or recurrent cancer as metastatic, and those who received chemotherapy in both settings as both. Patients were classifi ed as nonmetastatic if they had stage I -III breast, non -small cell lung, or colon cancer when they were treated or if they were treated within the fi rst 12 months from diagnosis of diffuse large B-cell lymphoma. They were classifi ed as metastatic if they had stage IV breast, non -small cell lung, or colon cancer. If chemotherapy was administered after the fi rst 12 months, the patient was categorized as having a recurrence. Chemotherapy was classifi ed as ever use of rituximab, platinum, 5-fl uorouracil, or other.
From the Editors
Outcomes
The main outcomes of the study were receipt of blood transfusion and diagnostic claim for venous thromboembolism (deep vein thrombosis and/or pulmonary embolism). We identified patients who received inpatient or outpatient blood transfusions between 1991 and 2002. A venous thromboembolism event required a billing claim (the first claim). A pulmonary embolism or deep vein thrombosis event required at least two claims ( 16 ) . An anemia event required at least two claims ( Supplementary Table 1 , available online). Patients were tracked until the end of follow-up, December 31, 2002, or death.
Statistical Analysis
Treatment with an erythropoiesis-stimulating agent and nontreatment were compared by use of 2 tests and univariate regression, with respect to clinical and demographic variables. We used multivariable logistic regression models to analyze the association of use of erythropoiesis-stimulating agents with clinical and demographic variables (for variables, see Table 1 ). We used time-dependent Cox proportional hazards models from the date of diagnosis to analyze the association of erythropoiesis-stimulating agent with venous thromboembolism and with overall survival. The assumption of proportionality was confirmed visually. Patients who had a deep vein thromboembolism before receiving an erythropoiesis-stimulating agent were classified as being erythropoiesis-stimulating agent negative in this analysis. Multivariable Cox proportional hazards models were used to evaluate the relationship of erythropoiesisstimulating agent dose (assessed as the number of claims) to a venous thromboembolism event and the relationship of erythropoiesisstimulating agent dose to receiving blood transfusions. These analyses were also performed stratified by age category (65 -69, 70 -74, 75 -79, or ≥ 80 years), extent of disease (metastatic, nonmetastatic, or both), and tumor type (colon, breast, lung, or lymphoma). A sensitivity analysis was performed by altering the number of claims for the outcome variables. Follow-up was available through December 31, 2002. We generated Kaplan -Meier curves and applied the log-rank test to compare rates of venous thromboembolism among patients who received erythropoiesis-stimulating agents within 3 months of diagnosis with those who did not, so that the time to event would be similar in both groups. In this analysis only, we excluded the 9870 patients who had had a venous thromboembolism before diagnosis to 3 months after diagnosis. We generated Kaplan -Meier curves to compare overall survival among patients who did and did not receive erythropoiesis-stimulating agents. All analyses were conducted with SAS, version 9.13 (SAS Institute, Cary, NC). All statistical tests were two-sided.
Results
We identified 56 210 individuals who were aged 65 years or older in the SEER -Medicare database, who met our inclusion criteria, and who received chemotherapy between January 1, 1991, and December 31, 2002. Of these patients, 15 346 (27%) received erythropoiesis-stimulating agents ( Table 1 ) . The proportion of patients receiving erythropoiesis-stimulating agents increased dramatically over time, from 141 (4.8%) of a total of 2902 patients in 1991 to 2849 (45.9%) of a total of 6183 patients in 2002 ( P < .001) ( Figure 1 ). By 2002, 1451 (54%) of the 2669 patients with metastatic cancer and 2672 (45%) of the 5868 with nonmetastatic cancer received erythropoiesis-stimulating agents during chemotherapy. In a multivariable analysis, use of erythropoiesis-stimulating agents was statistically significantly decreased among patients who lived in a nonmetropolitan area, compared with a metropolitan area (odds ratio [OR] = 0.83, 95% CI = 0.76 to 0.91). Use of these agents was increased in women compared with men, in patients with higher rather than lower socioeconomic status, in patients with more rather than fewer comorbid conditions, in patients who were diagnosed in a later year rather than in an earlier year, and in patients who had metastatic disease compared with nonmetastatic disease . Patients with breast, lung, or diffuse large B-cell lymphoma were more likely to receive an erythropoiesis-stimulating agent than patients with colon cancer ( Table 1 ) . Women with diffuse large B-cell lymphoma (OR = 1.15, 95% CI = 1.05 to 1.26), colon cancer (OR = 1.38, 95% CI = 1.25 to 1.54), or lung cancer (OR = 1.23, 95% CI = 1.14 to 1.32) were statistically significantly more likely to receive erythropoiesis-stimulating agents than men with the same disease.
The initial clinical trials ( 1 , 2 ) leading to FDA approval for the use of erythropoiesis-stimulating agents found a reduction in blood transfusions with use of these agents as the primary outcome. In contrast, in a population-based setting, we did not observe a change in the proportion (22%) of patients receiving chemotherapy who received at least one blood transfusion between 1991 and 2002. In fact, in the subset of patients with two claims for anemia or more, who were among the 25 464 patients in the original nine SEER sites, erythropoiesis-stimulating agent use increased from 8.5% to 60.5%. In this group of anemic patients, those who received erythropoiesis-stimulating agents had a higher transfusion rate than those who did not. Approximately 30% of patients in the erythropoiesis-stimulating agent group who received transfusions received them in the year before they received the erythropoiesis-stimulating agent, and approximately 50% received transfusions at the same time or during the year after they received the erythropoiesis-stimulating agent. Among both groups, transfusion rates decreased only slightly, but similarly, over time ( Figure 1 , B) .
From diagnosis through the end of follow-up, 5196 (11%) of the total of 47 342 patients had a new claim for venous thromboembolism.
Among the 12 522 patients who received erythropoiesis-stimulating agents, 1796 (14.3%) had a venous thromboembolism event compared with 3400 (9.8%) of the 34 820 patients who did not receive erythropoiesis-stimulating agents ( P < .001). In a time-dependent Cox proportional hazards model that evaluated time to fi rst venous thromboembolism event, use of erythropoiesis-stimulating agents (HR = 1.93, 95% CI = 1.79 to 2.07), advanced age (HR = 1.16, 95% CI = 1.07 to 1.23, for ages 70 -74 years; HR = 1.21, 95% CI = 1.11 to 1.30, for ages 75 -79 years; HR = 1.18, 95% CI = 1.07 to 1.28, for ages ≥ 80 years, all compared with ages 65 -69 years), black race (HR = 1.20, 95% CI = 1.07 to 1.35), radiation therapy (HR = 1.22, 95% CI = 1.15 to 1.30), increased comorbid conditions (HR = 1.32, 95% CI = 1.22 to 1.43), and recurrent or metastatic cancer (HR = 1.53, 95% CI = 1.43 to 1.64) and diagnosis of lung cancer (HR = 1.14, 95% CI = 1.00 to 1.29) were associated with an increased risk for venous thromboembolism ( Table 2 ). Patients with fi ve or more claims for use of erythropoiesis-stimulating agents had a stronger association (HR = 1.55, 95% CI = 1.44 to 1.66) with venous thromboembolism than those with fewer than fi ve claims (HR = 1.31, 95% CI = 1.19 to 1.44). A similar result was observed when the sample was limited to patients with nonmetastatic disease (for fi ve claims or more, HR = 1.72, 95% CI = 1.51 to 1.96; for fewer than fi ve, HR = 1.36, 95% CI = 1.17 to 1.58). The effect size for risk of venous thromboembolism was similar after altering the number of claims from two to three. The risk of a venous thromboembolism event after use of erythropoiesis-stimulating agents was slightly higher in patients with colon cancer (HR = 2.23, 95% CI = 1.88 to 2.65) ( Figure 2 ). When we stratifi ed the analyses by year of diagnosis and limited patient follow-up to 4 years, we found that for each time period, erythropoiesis-stimulating agent use was associated with at least a twofold increase in venous thromboembolism events. Survival free of venous thromboembolism for patients who received erythropoiesis-stimulating agents compared with those who did not was shorter ( P < .001, log-rank test) ( Figure 3 ) . No association between erythropoiesis-stimulating agent use and mortality was observed, however ( Figure 4 ).
Discussion
We found that the use of erythropoiesis-stimulating agents increased rapidly after FDA approval, with approximately 50% of patients with advanced cancer undergoing chemotherapy receiving erythropoiesis-stimulating agents by 2002. Despite erythropoiesis-stimulating agents being associated with a reduction in use of blood transfusions in clinical trials, the proportion of patients who received at least one blood transfusion remained constant during the 10-year study period, with slight decreases in the number of anemic patients who did and did not receive erythropoiesis-stimulating agents. In addition, our findings support the recent reports ( 7 , 8 ) that elderly patients with cancer who received erythropoiesis-stimulating agents as an adjunct to chemotherapy were at increased risk of developing venous thromboembolism. Similar to one subgroup analysis within a recent meta-analysis ( 17 ) that limited its analysis to patients who were undergoing chemotherapy, we did not observe an increase in risk of mortality that was associated with the use of erythropoiesisstimulating agents.
Reports of adverse events associated with a number of commonly used medications that appear years after the initial FDA approval have raised concerns about the drug evaluation process ( 18 -23 ) . Identifi cation of new toxic effects of FDA-approved drugs tends to increase distrust in the medical establishment. Erythropoiesis-stimulating agents were a prototypical example of the limitations of our current system. The initial approval of the erythropoiesis-stimulating agent erythropoietin for chemotherapyrelated anemia was based on pooled data from two randomized trials in which patients were evaluated for 12 weeks ( 2 , 24 , 25 ) . Subsequently, meta-analyses ( 8 , 9 ) that included thousands of patients from randomized controlled trials identifi ed an increased risk of venous thromboembolisms that was associated with use of erythropoiesis-stimulating agents.
Medications that are approved for the supportive care of patients with cancer often have short-term outcomes, but the risks after prolonged use are not evaluated. Unfortunately, many important questions cannot be addressed in premarketing studies, which are largely focused on demonstrating short-term effi cacy. This system failed to detect the risks associated with use of erythropoiesis-stimulating agents that did not come to light until * In this analysis, 11% had had either deep vein thrombosis or pulmonary embolism. Each variable was adjusted for the other listed characteristics and for Surveillance, Epidemiology, and End Results site. 5-FU = 5-fluorouracil; CI = confidence interval; ESA = erythropoiesis-stimulating agent; HR = hazard ratio.
years after the drugs were approved. A recent proposal in an editorial ( 23 ) calls for postmarketing studies of new drugs to address potential long-term toxic effects associated with new medications, including adequately powered safety studies, longterm studies of drugs for chronic diseases, epidemiological studies of rare adverse effects, and randomized trials that assess effi cacy. After stratifying by year since marketing approval for erythropoiesis-stimulating agents, we found that the association between use of these drugs and an increased risk of venous thromboembolism could be detected as early as 4 years after FDA approval. Thus, the use of claims data for monitoring outcomes appears to be warranted as a potential way for detecting longterm toxicities.
In the spring of 2007, the FDA published an alert after results of six trials ( 26 ) of erythropoiesis-stimulating agents showed a small increased risk tumor progression and/or decreased survival associated with the use of erythropoiesis-stimulating agents. This alert culminated in a black box warning about the potential for tumor promotion, decreased survival, and venous thromboembolism in erythropoiesis-stimulating agent users ( 27 ) . Their suggestions were to limit use of these drugs to specifi c tumor types, durations, doses, and targeted hemoglobin levels. In addition, for the fi rst time to our knowledge, the Center for Medicare and Medicaid Services proposed the elimination or limitation of coverage for erythropoiesis-stimulating agents as treatment for some cancers. In our analysis in this article, we did not detect an increased risk of death; however, our sample was limited to elderly cancer patients who were receiving chemotherapy. A recent metaanalysis ( 10 ) of individual data from patients who were treated with chemotherapy did not fi nd that increased mortality was associated with use of erythropoiesis-stimulating agents (HR = 1.04, 95% CI = 0.97 to 1.11).
We found greater use of erythropoiesis-stimulating agent among women with colon cancer, non -small cell lung cancer, and diffuse large B-cell lymphoma than among men with the same diseases. Among individuals older than 50 years, women have lower hemoglobin levels than men ( 28 ) . It is unclear whether this observation is related to differences in hormones, diet, or other factors. Our observation that patients residing in rural areas and patients older than 80 years were less likely to receive erythropoiesis-stimulating agents may indicate diffi culty in traveling to the clinic or physician ' s offi ce for injection of the erythropoiesis-stimulating agent.
Given the rapid rise in the use of erythropoiesis-stimulating agents since their approval by the FDA, we were surprised to fi nd that rates of red blood cell transfusion did not decrease substantially during this time. The Cochrane Review ( 7 ) of more than 30 trials, including more than 6000 patients, found that the use of erythropoiesis-stimulating agents was associated with a statistically signifi cantly reduced risk of blood transfusions (relative risk = 0.64). One possibility is that the patients in the placebo group of the clinical trial had a higher rate of transfusion than patients who are not on a clinical trial. In the original clinical trials ( 1 -3 ) , the blood transfusion rate was 40% -50% in patients who were randomly assigned to the placebo groups. Patients treated by physicians aware of the hypothesis may have been more inclined to proceed with transfusions than they would have been otherwise. We observed that, in the community, patients who required transfusions were those who were also treated with erythropoiesisstimulating agents, either before or after the transfusion.
Erythropoiesis-stimulating agents are of particular interest from a public policy perspective because of the costs associated with their use. The total US sales of erythropoiesis-stimulating agents increased from $6.4 billion in 2002 to $10 billion in 2006, accounting for a greater Medicare Part B expenditure than any other drug ( 29 ) . We speculate that this use was fueled by aggressive marketing to patients and physicians that focused on a promise of increased energy during chemotherapy treatment. It is estimated that direct medical care costs attributable to cancer now exceed $70 billion annually ( 30 ) , with large increases in cost for elderly patients ( 31 ) .
Our study had several limitations. Despite the value of the SEER -Medicare database, it has some limitations. The SEER database consists of data provided by hospital cancer registries that is obtained from patient charts. The Medicare database consists of reimbursement claims for medical care. As a result, it is possible that venous thromboembolism would be diagnosed but not refl ected in the billing claims. One study ( 16 ) has shown that claims data can be used effectively in the long term to capture chronic complications especially when the complication prompts an intervention, such as urethral strictures, but may not be so useful in Figure 2 . Risk of venous thromboembolism after treatment with an erythropoiesis-stimulating agent by age group and tumor type. Data are from individual multiple logistic regression models controlling for clinical and demographic variables (as shown in Table 1 ). Error bars = 95% confi dence intervals. capturing chronic symptoms, such as impotence or incontinence. This situation is also found with deep vein thrombosis and pulmonary embolism. In addition, investigators have shown that requiring two claims decreases the likelihood of misclassifi cation ( 16 ) . The SEER -Medicare database has been used by many investigators to evaluate late effects of therapy ( 32 -35 ) . It is also possible that instances of patients receiving erythropoiesis-stimulating agents were not captured in Medicare claims; however, because of the expense of the medications and the exclusion of patients with secondary insurance, we do not believe that this problem occurs for a large number of patients. It was possible that not all transfusions were captured because not all blood products are reimbursed fully by Medicare; however, a claim for both the transfusion and the cost for the infusion for the transfusion does usually generate claims data. Another major limitation of our study is that we could not ascertain hemoglobin levels for individual patients; however, at least one study ( 36 ) has shown that hemoglobin level is not associated with the risk of venous thromboembolism.
All association studies are limited by lack of certainty with regard to causality. Although the association is biologically plausible and short-term randomized controlled trials have established the association, it is unclear from observational studies whether the reason for administration of an erythropoiesis-stimulating agent places the patient at higher risk for venous thromboembolism or if the agent itself increases risk. This problem of confounding by indication is particularly true for patients with more claims for erythropoiesis-stimulating agents who may be sicker as a result of the underlying cancer. Unlike the clinical trials, patients who are treated in a community practice are given erythropoiesisstimulating agents intermittently; therefore, the length of time between dose and event varied. The increased risk of venous thromboembolism that we observed was slightly higher than that observed in the meta-analysis of randomized controlled trials in which patients were followed prospectively, but for a shorter period of time ( 9 ) . The patients in this analysis had a longer follow-up and were all older than 65 years, which may have also contributed to increased risk.
Our study demonstrated that the use of erythropoiesisstimulating agents increased rapidly in community practice after its approval in patients with both solid tumors and hematologic malignancy and among patients with either early-stage or advanced cancer who were receiving chemotherapy. Despite this increased administration to nearly half of all cancer patients, a substantial reduction in the use of blood transfusions was not observed. However, the increased risk of venous thromboembolism that was associated with use of an erythropoiesisstimulating agent, confi rming the association observed in the meta-analysis ( 9 ) . Further efforts at monitoring use and longterm toxicity of expensive oncology drugs should be put in place to ensure that for any drug the benefi ts outweigh the risks in community practice.
